Mount Sinai and Case Western researchers have found a new use for the dopamine receptor antagonist trifluoperazine: restoring the sensitivity of tumors to EGFR inhibitors. The key is trifluoperazine's off-target activity inhibiting the nuclear export of the tumor suppressor FOXO1.